Crisaborole is a phosphodiesterase 4 inhibitor indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older. It is available as ointment for topical use. MedsAcross supplies Crisaborole for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
EUCRISA is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older. EUCRISA is a phosphodiesterase 4 inhibitor indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
Source: US FDA prescribing information
Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor. PDE-4 inhibition results in increased intracellular cyclic adenosine monophosphate (cAMP) levels. The specific mechanism(s) by which crisaborole exerts its therapeutic action for the treatment of atopic dermatitis is not well defined.
Source: US FDA prescribing information
Apply a thin layer of EUCRISA twice daily to affected areas. Once clinical effect is achieved, consider reducing application to once daily. EUCRISA is for topical use only and not for ophthalmic, oral, or intravaginal use. • Apply a thin layer twice daily to affected areas. • Once clinical effect is achieved, consider reducing application to once daily. • For topical use only. • Not for ophthalmic, oral, or intravaginal use.
Source: US FDA prescribing information
EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation. Known hypersensitivity to crisaborole or any component of the formulation.
Source: US FDA prescribing information
Hypersensitivity reactions: If signs and symptoms of hypersensitivity occur, discontinue EUCRISA immediately and initiate appropriate therapy.
Source: US FDA prescribing information
The most common adverse reaction occurring in ≥1% in subjects is application site pain.
Source: US FDA prescribing information
Store at 20°C–25°C (68°F–77°F), excursions permitted to 15°C–30°C (59°F–86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Crisaborole, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Eucrisa 2% ointmentTopical | Pfizer Laboratories | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Crisaborole in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Crisaborole and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Crisaborole, including Eucrisa.
Yes. The US FDA first approved Crisaborole on 14 December 2016, according to Drugs@FDA.
No listed presentation of Crisaborole is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Crisaborole is classified under ATC code D11AH06 (Crisaborole).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.